Dr Travis Young | Vice President, Biologics
California Institute for Biomedical Research

Dr Travis Young, Vice President, Biologics, California Institute for Biomedical Research

Dr. Young received a PhD in chemical biology from The Scripps Research Institute and a BS in biochemistry from Boston College.  He is currently the Director of Protein Sciences at The California Institute for Biomedical Research.  Prior to joining Calibr he was a postdoc at Harvard Medical School in the department of Biological Chemistry and Molecular Pharmacology where he worked with Dr. Christopher T Walsh.  At Calibr he serves as the lead investigator on bispecific antibody and CAR-T cell programs and heads a group in antibody engineering and expression.  The group’s research focuses on the development of novel antibody-based therapeutics in the bispecific antibody and CAR-T cell fields.  This work has been awarded support from multiple funding bodies including the Wellcome Trust, NIH (NCI), Department of Defense, Mesothelioma Research foundation and the American Cancer Society.  His team has developed multiple preclinical assets that will be first-in-class molecules expected to enter the clinic over the next 2 years


West Coast Day 1 @ 17:20

Strategies for the development of safer and more effective CAR-T therapies

  • General strategies for CAR-T cell control
  • Defining small molecule vs antibody-based targeting – why we use Ab-based targeting.
  • Deep dive into the technicalities of designing these switches to control different targets
  • Universality of the platform and potential for use in solid tumors.
last published: 22/Nov/18 11:45 GMT

back to speakers

Sign Up for Event Updates

Contact us

To sponsor or exhibit contact:
Oliver Breed
+44 (0)207 092 1156


To speak:
Lauren Sheppard
+44 (0)207 092 1211